** Shares of drugmaker Vertex Pharmaceuticals VRTX.O fall 1.8% to $461 in morning trade
** Co on Monday reported Q4 profit of $3.98/shr, missing analysts' est. of $4.03/shr - as per LSEG data
** Q4 sales of co and partner CRISPR's CRSP.BN sickle-cell disease therapy, Casgevy, came in at $8 mln vs est. of $17.7 mln
** Brokerage TD Cowen says sales of Casgevy could be hurt by adoption and manufacturing-related challenges; does not expect VRTX to post billion-dollar revenues for the therapy
** VRTX forecast 2025 rev. of $11.75 bln to $12.0 bln, vs. est. of $11.84 bln
** Co said it aims to launch five new treatments by 2028, which includes a next-generation cystic fibrosis drug and its recently approved non-opioid painkiller, Journavx
** Stock has risen 11% in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。